Welcome to our dedicated page for Inogen SEC filings (Ticker: INGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Inogen Inc (INGN) SEC filings page on Stock Titan brings together the company’s regulatory disclosures as a Nasdaq-listed medical technology issuer. Inogen files annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K, along with other required documents, providing detailed insight into its respiratory care business for the homecare setting.
In its periodic reports, Inogen presents financial statements and operating data covering sales and rental revenue, gross profit, operating expenses such as research and development, sales and marketing, and general and administrative costs, as well as net income or loss, cash flows, and balance sheet information. Supplemental tables may break out revenue by category, including business-to-business domestic and international sales and direct-to-consumer and rental activity, reflecting how its respiratory products reach patients and providers.
Current reports on Form 8-K document material events, such as the release of quarterly financial results and certain leadership or governance changes. For example, Inogen has used Form 8-K to furnish press releases reporting results for quarters ended March 31, June 30, and September 30, 2025, and to describe appointments and designations of executive officers.
On Stock Titan, these filings are updated as they become available from EDGAR and are paired with AI-powered summaries that explain key points in accessible language. Users can quickly see what Inogen reports about its respiratory product portfolio, revenue mix between sales and rentals, operating trends, and significant corporate developments without reading every line of each document.
Investors researching INGN can use this page to access 10-K and 10-Q filings for a structured view of Inogen’s financial condition and risk disclosures, and Form 8-K filings for timely updates on results of operations and notable corporate events, all supported by AI-generated highlights.
Inogen, Inc. filed a current report to let investors know it has released preliminary, unaudited revenue results for its fourth quarter and full year ended December 31, 2025. The company communicated these figures in a press release dated January 12, 2026, which is included as Exhibit 99.1. The filing emphasizes that the amounts are preliminary, have not been audited, and may change once the annual financial statements are completed, so they provide only a partial view of the company’s financial performance. Inogen also clarifies that the press release and related information are being furnished, not filed, which affects how they are treated under securities laws and in future SEC filings.
Inogen Inc's Chief Commercial Officer reports stock transactions linked to vesting restricted stock units. On December 1, 2025, the officer acquired 31,566 shares of common stock at an exercise price of $0 when a portion of a time-based restricted stock award vested. On the same day, 12,943 shares were withheld and disposed of at $6.95 per share to cover tax withholding obligations.
After these transactions, the officer directly owned 37,246 shares of Inogen common stock and held 31,565 restricted stock units. Each restricted stock unit represents the right to receive one share of Inogen common stock, with one-third of the units vesting on each anniversary of the December 1, 2023 vesting commencement date, subject to continued service.
Inogen Inc. disclosed an insider equity transaction involving its CEO and President, who also serves as a director. On December 1, 2025, a portion of a time-based restricted stock unit award vested, resulting in the acquisition of 28,334 shares of common stock at an exercise price of $0. To satisfy tax withholding obligations related to this vesting, 13,817 shares were withheld at a price of $6.95 per share. Following these transactions, the reporting person held 86,291 shares of Inogen common stock directly and 28,333 restricted stock units, which represent a contingent right to receive the same number of shares as they vest over time under the award’s vesting schedule.
Inogen, Inc. (INGN) reported Q3 2025 results with total revenue of $92.4 million, up from $88.8 million a year ago. Net loss was $5.3 million and diluted loss per share was $0.20. Gross profit was $41.3 million, essentially flat year over year, as higher sales were offset by rental margin pressure.
Operating expenses fell modestly, narrowing the loss from operations to $7.1 million from $7.8 million. For the nine months, revenue reached $266.9 million with a net loss of $15.6 million, an improvement from $26.1 million last year.
Liquidity remained solid with cash and cash equivalents of $106.5 million and marketable securities of $16.7 million. Operating cash flow was an outflow of $10.3 million year to date. The company received $27.2 million from a common stock private placement at $10.36 per share in Q1 and paid a $13.0 million acquisition earnout. In August, Inogen settled the APT dispute for $1.75 million plus $0.67 million in legal costs. Shares outstanding were 27,148,482 as of October 31, 2025.
Inogen, Inc. (INGN) furnished a press release with Q3 2025 results. The company submitted an 8‑K under Item 2.02 to provide its financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and is dated November 5, 2025.
The company states this information, including Exhibit 99.1, is furnished and not deemed filed under Section 18 of the Exchange Act. An Inline XBRL cover page is included as Exhibit 104. The report was signed by Michael Bourque, Executive Vice President, Chief Financial Officer and Treasurer.
Michael J. Bourque, EVP, CFO & Treasurer of Inogen Inc. (INGN), acquired 1,500 shares of the company's common stock on 09/01/2025 at a price of $7.99 per share under the 2014 Employee Stock Purchase Plan. After the purchase, Mr. Bourque directly beneficially owned 49,146 shares. The Form 4 was executed by Mary Wright as Attorney-in-Fact and dated 09/03/2025. The filing indicates the transaction was reported under Section 16 and that the purchase was made pursuant to a company plan; no derivatives, dispositions, or additional transactions are reported on this form.
Kevin P. Smith, Executive Vice President, Business Development, General Counsel and Secretary of Inogen Inc. (INGN), reported transactions on September 1, 2025 that changed his beneficial ownership. He purchased 1,500 shares under the companys 2014 Employee Stock Purchase Plan at $7.99 per share and received 18,135 restricted stock units (each representing one share) that vested in part on that date. To satisfy tax withholding on a portion of the vested awards, 8,043 shares were withheld. After these transactions Mr. Smith beneficially owns 36,271 shares.
The restricted stock units vest in three equal annual tranches, with one-third vested on September 1, 2025 and the remainder subject to continued service on the same annual date.
Kevin Raymond Smith, CEO, President and a director of Inogen Inc (INGN), reported acquiring 1,500 shares of Common Stock on 09/01/2025 at a purchase price of $7.99 per share under the company’s 2014 Employee Stock Purchase Plan. After the purchase, Mr. Smith beneficially owns 71,774 shares directly. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 09/03/2025. The filing indicates the transaction was made pursuant to a written plan intended to satisfy Rule 10b5-1(c)'s affirmative defense.
Inogen, Inc. reported consolidated second-quarter revenue of $92.3 million, up 4.0% year-over-year, driven by higher sales revenue of $79.2 million as unit shipments rose to ~49,000 systems versus ~41,300 a year earlier. Rental revenue declined 8.6% to $13.1 million, reflecting a shift toward lower private-payor reimbursement.
Gross margin narrowed to 44.8% from 48.1%, attributed to customer/channel mix and higher materials costs including semiconductor premiums. The company reported a net loss of $4.152 million in Q2 and a six-month loss of $10.326 million, while operating activities used $12.44 million of cash year-to-date. Liquidity remained solid with cash and cash equivalents of $103.7 million and total cash, cash equivalents and restricted cash of $104.96 million.
Corporate developments included a $27.21 million private placement with Yuwell, a Strategic Collaboration Agreement with Yuwell to broaden product distribution and accelerate Chinese market entry, and completion of earnout payments related to the Physio-Assist acquisition. Management is evaluating recent U.S. tax legislation and continues to record a valuation allowance on deferred tax assets.